Peer-reviewed veterinary case report
The impact of tau deletion on Huntington's disease: An in vivo perspective.
- Journal:
- Molecular therapy : the journal of the American Society of Gene Therapy
- Year:
- 2026
- Authors:
- Lepinay, Eva et al.
- Affiliation:
- Dé · Canada
- Species:
- rodent
Abstract
Although an emerging body of evidence suggests that abnormal forms of tau are present and contribute to Huntington's disease (HD)-a genetic neurodegenerative disorder primarily characterized by the aggregation of the mutant huntingtin (mHtt) protein affecting cognitive, motor, and psychiatric function-it is not clear to what extent this is relevant to the disease phenotype, and hence future treatments. We therefore generated a novel murine model by crossing heterozygous zQ175 knockin HD mice with homozygous tau knockout mice (mTKO). Tau deletion exacerbated both motor and cognitive deficits in zQ175/mTKO mice, which was accompanied by increased mHtt aggregation and alterations in microtubule dynamics, including dysregulated expression of microtubule-associated proteins, aberrant perinuclear β-tubulin accumulation, and microtubule destabilization. Combined, our findings unveil a previously unrecognized protective role of non-hyperphosphorylated tau in maintaining cytoskeletal homeostasis in HD and highlight a functional overlap between tau and huntingtin in regulating aggregate dynamics and cytoskeletal integrity. Our findings complement previous reports suggesting that reducing tau levels could mitigate disease pathology in HD mouse models.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/41318997/